«CANINE BLADDER CANCER by Deborah W. Knapp, DVM, Dipl. ACVIM Cancer of the urinary tract in dogs can affect the kidneys, ureters, urinary bladder, ...»
In the Purdue Comparative Oncology Program at Purdue University, we study specific forms of naturally-occurring cancer in pet dogs in order to learn new information to help animals and to help human cancer patients. This is possible because certain naturally occurring canine cancers greatly resemble that same form of cancer in humans. This is true with bladder cancer. Canine TCC is almost identical to human invasive TCC in histopathologic characteristics, molecular features studied to date, biologic behavior (sites and frequency of metastasis), and response to medical therapy. Our laboratory is studying the risk factors (environmental and genetic) for TCC, methods to detect TCC earlier, and methods to more effectively treat TCC. These studies are expected to benefit both animals and humans with cancer. In fact, our work has already led to clinical trials in humans with TCC at the Indiana University School of Medicine.
Canine Bladder Cancer Clinic at Purdue University. Within the Oncology Section in the Purdue University Veterinary Teaching Hospital, a Canine Bladder Cancer Clinic has been established to care for dogs that have TCC or dogs suspected of having TCC. The clinic is staffed by Dr. Deborah Knapp, other veterinarians specializing in oncology, veterinary technicians, and assistants. Diagnostic procedures including cystoscopy, cancer staging tests, and multiple types of therapy are offered. The Canine Bladder Cancer Clinic also has ongoing clinical trials to help dogs with TCC while learning new information that can help other dogs and potentially humans with this cancer. Veterinarians in the Bladder Cancer Clinic work closely with primary care veterinarians in the dog’s home town to provide the most complete care. If you would like to schedule an appointment, please call the reception staff at 765 494-1107, or you may call our Clinical Trials Coordinator, Ms. Patty Bonney at 765 494-1130.
Recent Publications and Selected Earlier Publications Related to Bladder Cancer:
Dhawan D, Ramos-Vara JA, Naughton JF, Cheng L, Low PS, Rothenbuhler R, Leamon CP, Parker N, Klein PJ, Vlahov IR, Reddy JA, Koch M, Murphy L, Fourez LM, Stewart JC, Knapp DW. Targeting folate receptors to treat invasive urinary bladder cancer. Cancer Res 2013;73:875-84.
Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, Lucroy MD, Greenberg CB, Greene SN, Abbo AH, Hanson PD, Alva R, Bonney PL. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with rransitional cell carcinoma of the urinary bladder. J Vet Intern Med 2013; 27:126–133.
Higuchi T, Burcham GN, Childress MO, Rohleder JJ, Bonney PL, Ramos-Vara JA, Knapp DW.
Characterization and treatment of transitional cell carcinoma of the abdominal wall in dogs: 24 cases (1985-2010). J Am Vet Med Assoc. 2013; 15;242:499-506.
Dhawan D, Ramos-Vara JA, Hahn NM, Waddell J, Olbricht GR, Zheng R, Stewart JC, Knapp DW.
DNMT1: An emerging target in the treatment of invasive urinary bladder cancer. Urol Oncol 2012 May 18.
[Epub ahead of print].
Zhang J, Wei S, Liu L, Nagana Gowda GA, Bonney P, Stewart J, Knapp DW, Raftery D. NMR-based metabolomics study of canine bladder cancer. Biochim Biophys Acta 2012;1822:1807-14.
Hahn NM, Bonney PL, Dhawan D, Jones DR, Balch C, Guo A, Hartman-Frey C, Fang F, Parker HG, Kwon EM, Ostrander EA, Nephew KP, Knapp DW. Subcutaneous 5-azacitidine treatment of naturallyoccurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. J Urol 2012;187:302-9.
McMillan SK, Knapp DW, Ramos-Vara JA, Bonney PL, Adams LG. Outcome of urethral stenting for management of obstruction secondary to transitional cell carcinoma in 19 dogs (2007-2010). J Amer Vet Med Assoc 2012;241:1627-32.
Naughton JF, Widmer WR, Constable D, Knapp DW. Accuracy of three-dimensional and twodimensional ultrasonography in measuring tumor volume in dogs with transitional cell carcinoma of the urinary bladder. Am J Vet Research 2012;73:1919-24.
Childress MO, Adams LG, Ramos-Vara J, Freeman LJ, He S, Knapp DW. Comparison of cystoscopy vs surgery in obtaining diagnostic biopsy specimens from dogs with transitional cell carcinoma of the urinary bladder and urethra. J Amer Vet Med Assoc 2011;239:350-6.
McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Amer Vet Med Assoc 2011;239:1084-9.
Arnold EA, Childress MO, Fourez LM, Tan KM, Stewart JC, Bonney PL, Knapp DW. Phase II clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 2011;
Abbo AH, Jones DR, Masters AR, Stewart JC, Fourez L, Knapp DW. Phase I clinical trial and pharmacokinetics of intravesical Mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder. J Vet Intern Med 2010 24:1124-30.
Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, Zheng R, Loman RA, Foster RS, Knapp DW. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 2010;9:1371-1377.
Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R, Knapp DW. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement animal model of invasive urinary bladder cancer. Urolog Oncol 2009; 27:284-292.
Dill AL, Ifa DR, Manicke NE, Costa AB, Ramos-Vara JA, Knapp DW, Cooks RG. Lipid profiles of canine invasive transitional cell carcinoma of the urinary bladder and adjacent normal tissue by desorption electrospray ionization imaging mass spectrometry. Analytical Chemistry 2009; 81:8758-8764.
Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 2008, 7:897-904.
Wilson CR, Regnier FE, Knapp DW, Raskin RE, Andrews DA, Hooser SB. Glycoproteomic profiling of serum peptides in canine lymphoma and transitional cell carcinoma. Vet Comp Oncology 2008; 6:171Knapp DW, Adams LG, Degrand AM, Niles JD, Ramos-Vara JA, Weil AB, O'Donnell MA, Lucroy MD.
Frangioni JV. Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. Eur Urol 2007; 52:1700-1708.
Mohammed SI, Deepika D, Abraham S, Snyder PW, Waters DJ, Lu M, Wu L, Zheng R, Stewart J, Knapp DW. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 2006; 5:329-336.
Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006;12:353-360.
Boria PA, Glickman NW, Schmidt BR, Widmer WR, Mutsaers AJ, Adams LG, Snyder PW, DiBernardi L, de Gortar AE, Bonney PL, *Knapp DW. Carboplatin and piroxicam in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
Raghavan M, Knapp DW, Bonney PL, Dawson MH, Glickman LT. Evaluation of the effect of dietary vegetable consumption on reducing risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc 2005;22:94-100.
Raghavan M, Knapp DW, Dawson MH, Bonney PL, Glickman LT. Topical spot-on flea and tick products and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terrier dogs. J Am Vet Med Assoc 2004;225:389-94.
Glickman LT, Raghavan M, Knapp DW, Bonney PL, Dawson MH. Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terrier dogs. J Am Vet Med Assoc 2004;1290-1297.
Mohammed SI, Craig BA, Mutsaers AJ, Glickman NW, Snyder PW, deGortari AE, Schlittler DL, Coffman KT, Bonney PL, Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003;2:183-188.
Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL, Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.
Knapp DW, Glickman NW, DeNicola DB, Bonney PL, Lin TL, Glickman LT. Naturally-occurring canine transitional cell carcinoma of the urinary bladder, a relevant model of human invasive bladder cancer.
Invited submission to Urol Oncol 2000;5:47-59.
Knapp DW, Richardson RC, Chan TCK, Bottoms GD, Widmer WR, DeNicola DB, Teclaw R, and Bonney PL. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
Knapp, DW, Richardson RC, Bottoms GD, Teclaw R, Chan TC. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.